I completed my medical residency in 1995 (St. Elizabeth's Medical Center, Boston, MA), cardiology fellowship in 1998 (University of Massachusetts Medical Center, Worcester, MA) and cardiac electrophysiology fellowship in 1999 (Massachusetts General Hospital, Boston, MA).
I am currently an Assistant Professor in Medicine, Harvard Medical School, Boston, MA. I am a Staff Cardiac Electrophysiologist and the Director of Pacemaker and ICD Clinic, Massachusetts General Hospital, Boston, MA.
Block HF Clinical Trial. This is a multicenter study to test the hypothesis that patients with mild to moderate symptoms of heart failure, NYHA Class I, II, and III, some degree of left ventricular dysfunction (LVEF < 50%) and AV block will benefit from biventricular pacing compared to right ventricular pacing, as evidenced by a slowing in the progression of heart failure in patients receiving biventricular pacing. This benefit will be demonstrated using a composite endpoint of mortality, morbidity and cardiac function.
VEST. This is a multicenter NIH funded study looking into reducing the risk of sudden cardiac death in post-MI patients who have a reduced LVEF < 35%. These patients will be randomized to receive a LifeVest external defibrillator as opposed to medical therapy.
Role: Principal investigator for Massachusetts General Hospital.
Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, Sanborn DM, Picard MH, Vlahakes GJ, Das S, Mela T. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. AJC 2009;104(1):128-132.
Merchant FM, Heist EK, McCarty D, Kumar P, Das S, Blendea D, Ellinor PT, Mela T, Picard MH, Ruskin JN, Singh JP. Impact of segmental left ventricle lead position on cardiac resynchronization therapy outcomes. Heart Rhythm. 2010 May;7(5):639-44.
Complication Rates Associated with Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures. Results from the REPLACE Registry. Circ 2010: 122;1553-1561.
Experts from the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care present insights and opinions on methods for treating refractory heart failure, genetically determined arrhythmias and atrial fibrillation in an integrated, multispecialty program.